ADELAIDE, Australia / RankWire.AI / – Australian scientists have uncovered a molecular switch that influences the dissemination of aggressive tumors, pointing toward a new potential approach to preventing secondary cancers. Their research, published in EMBO Molecular Medicine, features investigators from Adelaide University and the Olivia Newton-John Cancer Research Institute. The team demonstrated that restoring the activity of a crucial regulatory molecule called miR-342 greatly diminishes tumor metastasis. These results suggest a promising new method to address triple-negative breast cancer by targeting dormant cancer cells before they develop into lethal lesions in distant organs.
Although triple-negative breast cancer represents 10% to 15% of Australia’s roughly 21,000 annual breast cancer cases, it accounts for a disproportionate share of mortality. This subtype is characterized by the absence of estrogen, progesterone, and HER2 receptors, which makes conventional hormone-targeted therapies ineffective. The researchers showed that when miR-342 levels decrease, a cancer-promoting pathway named E2F becomes hyperactive. This overactivity facilitates dormant cancer cells to spread and establish dangerous secondary tumors throughout the body.
Targeted Treatments Offer New Possibilities for High-Risk Metastasis Prevention
In experiments with pre-clinical models, increasing miR-342 levels led to a marked reduction in the spread of cancer to distant sites. Additionally, the research revealed that palbociclib, an existing CDK4/6 inhibitor drug currently approved for hormone receptor-positive cancers, significantly slowed down metastatic tumor growth in models with low miR-342 expression. These findings indicate that measuring miR-342 could enable clinicians to repurpose existing drugs for treating patients at high risk of metastasis.
Associate Professor Philip Gregory from Adelaide University’s Centre for Cancer Biology, who is a co-senior author, stressed that metastasis prevention remains the greatest challenge in managing aggressive breast cancers. Gregory pointed out that since palbociclib inhibits the overactive E2F pathway, administering it after cancer cells have spread can prevent the expansion of microscopic deposits. Rather than solely aiming to shrink primary tumors, this approach halts the progression of microscopic secondary cancers into life-threatening conditions.
Pre-Clinical Data Published in Peer-Reviewed EMBO Molecular Medicine
The research team emphasized that the biological diversity of triple-negative breast cancer has historically hindered the development of universal targeted therapies. By identifying a shared biological vulnerability within a specific patient subgroup, the study paves the way for personalized treatment strategies. As Australian scientists explore a promising new method to combat triple-negative breast cancer, efforts are underway to validate these findings using patient-derived models ahead of clinical testing.
Medical oncologists and cancer research organizations across Australia have expressed support for the new insights, highlighting the urgent need for expanded treatment options when standard therapies fall short. The research team intends to collaborate with international clinical networks to expedite biomarker screening processes. Confirming the effectiveness of miR-342 testing could soon enable doctors to identify suitable candidates for targeted CDK4/6 inhibitor treatments during early intervention stages.